Table 2 Prognostic factors: univariate analysis
Characteristics | Local control | Overall survival | |||
|---|---|---|---|---|---|
2-year (%) | *P-value | 2-year (%) | *P-value | ||
Age (years) | ≤ 60 | 79.5 | 59.6 | ||
> 60 | 92.8 | 0.019 | 66.3 | NS | |
Gender | Male | 83.3 | 57.8 | ||
Female | 95.7 | NS | 76.8 | NS | |
Diagnosis history at SBRT | Initially diagnosed | 96.2 | 67.9 | ||
Recurrence | 82.3 | NS | 60.3 | NS | |
Child-Turcotte-Pugh score | A5, 6 | 85.3 | 60.1 | ||
B7 | 100.0 | NS | 87.5 | NS | |
Portal vein tumor thrombosis | Yes | 88.9 | 62.9 | ||
No | 86.4 | NS | 62.5 | NS | |
Alpha-fetoprotein (IU/ml) | ≤ 200 | 88.4 | 66.3 | ||
> 200 | 81.5 | NS | 53.8 | NS | |
AJCC stage | T1 | 93.7 | 71.3 | ||
T2, 3 | 73.2 | 0.031 | 53.8 | NS | |
BCLC stage | A | 93.7 | 74.7 | ||
B, C | 78.8 | 0.018 | 51.0 | 0.011 | |
Okuda stage | I | 89.1 | 65.4 | ||
II | 77.9 | NS | 55.0 | NS | |
CLIP score | 0 | 85.1 | 66.6 | ||
1, 2 | 88.6 | NS | 59.4 | NS | |
Longest diameter (cm) | ≤ 5.0 | 90.2 | 69.4 | ||
> 5.0 | 63.3 | 0.015 | 33.3 | 0.012 | |
No. of previous TACE sessions | ≤ 2 | 95.7 | 69.6 | ||
> 2 | 77.2 | 0.022 | 54.9 | 0.023 | |
SBRT dose (Gy) | < 45 | 64.3 | 30.0 | ||
45–54 | 78.3 | 0.009 | 64.3 | <0.001 | |
> 54 | 100.0 | 71.3 | |||